An observational study in Prostate Cancer, sponsored by Clinique Mutualiste Chirurgicale de la Loire. Terminated at 15 sites in France. Open to male participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2015-06-04.
Sponsored by Clinique Mutualiste Chirurgicale de la Loire · Observational
Among 509 studies in Prostatic Neoplasms with a site in France — 92 open to participants now, 156 under way, 50 of them phase 3. Prostatic Neoplasms · France.
Among the 509 studies in Prostatic Neoplasms with a site in France, this one is the 65th largest by enrollment of the 99 observational ones that give a count, is one of 8 that started in 2007, is one of 99 observational ones, and was the 67th registered.
7,046 studies on the registry are indexed under Prostatic Neoplasms; 1,580 are open to participants now.
Browse Prostatic Neoplasms studies →92 of the 509 studies in Prostatic Neoplasms with a site in France are open now. Recruiting first, the newest first:
AstraZeneca · Sites in France, United States, Austria and 18 more countries
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD · Sites in France, Germany, Italy and 2 more countries
Institut Cancerologie de l'Ouest · Sites in France
AstraZeneca · Sites in France, United States, Australia and 21 more countries
Assistance Publique - Hôpitaux de Paris · Sites in France
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 928 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 74 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
509 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 106 · Phase 3 149 · Phase 4 12
First in 1996; this study’s year is marked. 8 started in 2007.
This study's enrollment of 100 is below the median of 200 across 1,310 observational studies indexed under Prostatic Neoplasms.
Median enrollment 185 across the 405 interventional studies, 183 across the 99 observational. Of the 320 that completed or were terminated, 104 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
234 of 509 have an industry lead sponsor. The 10 most frequent:
Clinique Mutualiste Chirurgicale de la Loire is the lead sponsor of 3 studies on the registry; none are open to participants now.
Clinique Mutualiste Chirurgicale de la Loire has 1 study filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
38 of the studies in Prostatic Neoplasms with a site in France that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT04691804Phase 3Jiangsu HengRui Medicine Co., Ltd.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT06551324Phase 3PfizerA Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | 2027-02-28 |
| NCT06122584Phase 3ABX advanced biochemical compounds GmbHDiagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer | 2027-03 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
Among the 509 studies in Prostatic Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study concern a prospective cohort pf patients with latent prostate cancer. We study the specific survival at 10 years of patients who accept an active control.Patients inclusion are realized in 2 stages:
If progression of cancer happens during the 10 years control, active control will be stopped and patient will be treated by surgery and chemotherapy.
This study concern the active control during 10 years of patient with latent prostate cancer who accept not be treated immediately.
patients with latent prostate cancer who agree to be controlled instead of to be immediately treated for this cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient with latent prostate cancer who agree to be controled instead of to be treated
Procedure: prostate biopsy
patient of control group will have : * 1 prostate biopsy 3 months after diagnostic biopsy * 1 prostate biopsy each year during 2 years * 1 prostate biopsy each 2 years during 8 years
Evaluates specific survival to 10 years
Time frame: 10 years
To evaluate acceptation of 2nd biopsy to confirm latent cancer
Time frame: 10 years
To evaluate global survival of patient in control
Time frame: 10 years
To evaluate the survival of patient with a secondary active treatment after a control period
Time frame: 10 years
To evaluate delay to secondary treatment after a period control
Time frame: 10 years
To evaluate survival rate without biological or clinical progression of cancer
Time frame: 10 years
To evaluate quality of life
Time frame: 10 years
The record gives a start of Dec 2007, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinique Mutualiste Chirurgicale de la Loire